Targets › SOD3
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Jan 2027.
Secreted antioxidant enzyme that acts as the primary scavenger of superoxide radicals in the extracellular space, converting them to hydrogen peroxide and thereby protecting tissues from oxidative damage. Also preserves nitric oxide bioavailability by preventing the formation of harmful peroxynitrite. (UniProt, P08294)
Open in Phaseline: the race on SOD3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | superoxide dismutase skin spray antioxidant enzyme that catalyzes the dismutation of superoxide radicals | SOD1, SOD2, SOD3 | Phase 2 | Radiation-induced Dermatitis | Jan 2027 |
Radiation-induced Dermatitis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.